The Institute for Clinical and Economic Review (ICER) will assess the comparative clinical effectiveness and value of elagolix (AbbVie) for management of endometriosis with associated pain. The FDA’s decision on whether to approve elagolix is expected during the second quarter of 2018.
An Open Input period begins today, and is intended to allow stakeholders to share key information relevant to the development of the evidence report. Comments on elagolix and on managing endometriosis will be accepted from all interested stakeholders until Jan. 8. During this time, ICER will also contact key patient groups and clinical experts to gain further insights on the patient perspective and clinical context of treatment.
